Jennifer L. Taubert
Known title: EVP, WW Chair, PharmaceuticalsCIK: 0001745938
Associated companies
Transaction History
| JNJ | ▲ Buy | Option Exercise | 15,000 | $1.7M | 8/17/2026 | View on chart |
| JNJ | ▼ Sell | Open Market | 15,000 | $4.0M | 8/17/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,594 | $0 | 2/15/2026 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 816 | $199K | 2/15/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,847 | $0 | 2/15/2026 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 945 | $230K | 2/15/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 27,412 | $0 | 2/13/2026 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 13,547 | $3.3M | 2/13/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,302 | $0 | 2/13/2026 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 409 | $100K | 2/13/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 56,471 | $5.8M | 9/4/2025 | View on chart |
| JNJ | ▼ Sell | Open Market | 56,471 | $10.0M | 9/4/2025 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 651 | $102K | 2/18/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,594 | $0 | 2/15/2025 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 410 | $64K | 2/14/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 4,053 | $0 | 2/14/2025 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 1,348 | $211K | 2/14/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 15,465 | $0 | 2/14/2025 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 7,911 | $1.2M | 2/14/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,302 | $0 | 2/13/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 58,504 | $5.9M | 2/7/2025 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 47,436 | $7.3M | 2/7/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,302 | $0 | 2/13/2024 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 666 | $105K | 2/13/2024 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 3,769 | $0 | 2/12/2024 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 13,403 | $2.1M | 2/12/2024 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 22,433 | $0 | 2/12/2024 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 59,397 | $5.4M | 2/9/2024 | View on chart |
| JNJ | ▼ Sell | Open Market | 59,397 | $9.3M | 2/9/2024 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 3,739 | $0 | 2/8/2024 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 1,913 | $299K | 2/8/2024 | View on chart |
| JNJ | ▲ Buy | Grant | 21,422 | $0 | 2/13/2023 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 10,569 | $1.7M | 2/13/2023 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 3,570 | $0 | 2/10/2023 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 1,289 | $209K | 2/10/2023 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 76,923 | $5.6M | 11/22/2022 | View on chart |
| JNJ | ▼ Sell | Open Market | 76,923 | $13.6M | 11/22/2022 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 18,064 | $0 | 2/15/2022 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 8,841 | $1.5M | 2/15/2022 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 3,297 | $0 | 2/14/2022 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 1,190 | $201K | 2/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Johnson & Johnson: Key Takeaways for Long-Term Investors
Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.
Johnson & Johnson: Key Takeaways for Long-Term Investors. Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.